Global Ganja Report

In the near future, the CBD, THC or other cannabinoids you consume in edibles or medications may not be derived from cannabis at all, but grown in a laboratory.

Kevin Chen, CEO and co-founder of Hyasynth Bio, describes the Montreal-based start-up as "focused on engineering strains of yeast to produce the active compounds of cannabis without having to grow plants."

Protests have spread across the country in response to the death of George Floyd at the hands of Minneapolis police—a haunting crystallization of institutionalized racism in law enforcement. The protests have been punctuated by looting in many cities, and cannabis businesses have not been spared. How the industry reacts at this moment will reveal much about the soul of America's cannabis community.

If there is one person with a claim to reviving the pharmacopoeia of cannabis in the post-prohibition age—and thereby undermining prohibition's pseudo-scientific foundations—that person was Tod Mikuriya. The Berkeley psychiatrist, who died in 2007, was hailed as the grandfather of the medical marijuana movement, backing up the activists with unimpeachable scholarly chops—to the rage of the Drug War establishment.

A verdict against glyphosate producer Monsanto in a case brought by a cancer sufferer has brought world attention to the dangers of pesticides and herbicides. This is a question with implications already felt in the cannabis industry—both legal and illegal.

A figure from the Bay Area cannabis industry was embroiled in America's fast-escalating culture wars when she threatened to call the police on a young Black girl selling water on a San Francisco street. In the outcry, she has stepped down from her own company—and helped draw a line over what behavior is considered acceptable in the cannabis community.

For a generation now, science has known of two cannabinoid receptors—specialized protein molecules that interact with the active compounds in the cannabis plant for the human body. These are CB1 and CB2, both discovered in the early '90s. Now there is growing awareness of a third such receptor that was identified in 2007. This receptor, GPR55, may be key to understanding a wide spectrum of therapeutic applications for cannabinoids—and especially the non-psychoactive cannabidiol, or CBD.

The House and Senate appropriations leadership has hammered out a budget bill that includes an historic amendment to curb federal Department of Justice (DoJ) enforcement in medical marijuana states. The measure, which was originally passed by the House in May with a 219-189 vote, aims to prohibit the DoJ from spending taxpayer money to undermine state medical marijuana laws. "This is great news for medical marijuana patients all across the country," said Rep. Sam Farr (D-CA), one of the co-authors of the House measure. "This amendment protects patients while the federal government catches up with the views of the American people. Patients will have access to the care legal in their state without fear of federal prosecution. And our federal dollars will be spent more wisely on fighting actual crimes and not wasted going after patients."

In an unprecedented 219-189 floor vote late May 29, the House of Representatives approved the end of funding for Department of Justice (DoJ) enforcement in medical marijuana states. Advocates are hailing the vote as a major victory that signals a shift in the approach Congress is taking on this issue. The vote was on Amendment No. 25 to the Commerce, Justice & Science (CJS) appropriations bill. One hundred seventy Democrats and 49 Republicans voted in favor of the amendment. "This Congressional vote is a huge victory for patients," said Steph Sherer, executive director of Americans for Safe Access. "No longer will we have to look over our shoulder and worry when the next raid or indictment will prevent us from safely and legally accessing our medicine. This is a game-changer that paves the way for much more policy change to come."